Amneal Pharmaceuticals, Inc (AMRX) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

21/25

Growth 5 Margin 4 Expansion 5 Platform 2 Financial 5

latest quarter score

Earnings Reports

21
Amneal (AMRX) Q2 2026: Biosimilar Pipeline Expands to Six Launches, Unlocking $14B Market Access
July 30, 2026
24
Amneal (AMRX) Q1 2026: Biosimilars to Surpass $1B by 2030 as Kashiv Deal Reshapes Growth Trajectory
May 01, 2026
23
Amneal Pharmaceuticals (AMRX) Q4 2025: Specialty Segment Jumps 38% as Complex Launches Reshape Growth Mix
February 27, 2026
20
Amneal Pharmaceuticals (AMRX) Q3 2025: Biosimilar Pipeline Expands to Six as Guidance Rises Again
October 30, 2025
21
Amneal (AMRX) Q2 2025: Gross Margin Expands 470bps as Specialty Growth and U.S. Manufacturing Drive Guidance Raise
August 05, 2025
22
Amneal (AMRX) Q2 2025: Gross Margin Up 470bps as Specialty and Biosimilars Drive Next-Phase Growth
August 05, 2025
22
Amneal (AMRX) Q1 2025: Biosimilars Top $160M as U.S. Manufacturing Drives Margin Expansion
July 06, 2025

Browse all companies